IM
Immunome, Inc.
IMNM · NASDAQ
$23.93 -0.71% (-$0.17)
1M -21.35%
Market Cap $2.29B
P/E Ratio -
Div. Yield -
ROE 50.56%
Piotroski F-Score Weak
2/9Valuation
46 /100
Fair P/B 4.36x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 236.47%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 51.06%
ROE 50.56%
ROA 44.98%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 15.08x
Int. coverage N/A
Stability
10 /100
Unstable Beta 2.13x
EPS volatility 63.65%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na IMNM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Clay Siegall
Employees
247
Headquarters
Bothell
Nadcházející události
05 LIS
Earnings
Upcoming earnings report